News - PAK4 deletion - LARVOL VERI

almost2years

Remodeling of the tumor microenvironment through PAK4 inhibition sensitizes tumors to immune checkpoint blockade. (PubMed, Cancer Res Commun)

In addition, we validated genetically and pharmacologically that inhibition of PAK4 kinase activity is sufficient to improve anti-tumor efficacy of anti-PD-1 blockade in multiple melanoma mouse models. Therefore, this study provides novel insights into the mechanism of action of PAK4 inhibition and provides the foundation for a new treatment strategy that aims to overcome resistance to PD-1 blockade by combining anti-PD-1 with a small molecule PAK4 kinase inhibitor.

almost 2 years ago

Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Checkpoint block

CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CCR7 (Chemokine (C-C motif) receptor 7) • ITGAE (Integrin Subunit Alpha E)

PAK4 deletion • CCR7 expresion

almost4years

Comprehensive Profiling of Genomic and Transcriptomic Differences between Risk Groups of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma. (PubMed, J Pers Med)

The low-risk groups of both LUAD and LUSC tend to have a higher number of SNVs, CNVs, and DEGs. The signature genes and altered genes have the potential to be used as diagnostic and prognostic biomarkers for personalized oncology.

almost 4 years ago

Journal

KRAS (KRAS proto-oncogene GTPase) • PTEN (Phosphatase and tensin homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • RBM10 (RNA Binding Motif Protein 10) • KDM5C (Lysine Demethylase 5C) • SOX2 • PSMD4 (Proteasome 26S Subunit Non-ATPase 4)

KRAS mutation • EGFR mutation • CDKN2A deletion • HRAS mutation • PAK4 deletion • EGFR mutation + KRAS mutation • PSMD4 amplification

4years

[VIRTUAL] Comprehensive Genomic Sequencing in Thymic Epithelial Tumors: Identification of Multiple Poor Prognosis Biomarkers in Chinese Patients (IASLC-WCLC 2020)

The most altered genes are focused on signal pathways of cell cycle control, Chromatin remodeling/DNA methylation, PI3K/AKT1/MTOR, MAP kinase signaling and others.In addition, we firstly identified multiple poor prognosis biomarkers in Chinese thymic epithelial tumors patients. These poor prognosis biomarkers are mainly enriched in cell cycle control and PI3K/AKT1/MTOR pathways.

4 years ago

Clinical • Tumor mutational burden

TP53 (Tumor protein P53) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • ASXL1 (ASXL Transcriptional Regulator 1) • MTAP (Methylthioadenosine Phosphorylase) • BAP1 (BRCA1 Associated Protein 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • TSC2 (TSC complex subunit 2) • STAG2 (Stromal Antigen 2) • MLL2 (Myeloid/lymphoid or mixed-lineage leukemia 2) • EPHB4 (EPH receptor B4)

TP53 mutation • ASXL1 mutation • CDKN2A deletion • KMT2D mutation • BAP1 mutation • HRAS mutation • PAK4 deletion • STAG2 mutation

FoundationOne® CDx

4years

EWSR1-PATZ1-rearranged sarcoma: a report of nine cases of spindle and round cell neoplasms with predilection for thoracoabdominal soft tissues and frequent expression of neural and skeletal muscle markers. (PubMed, Mod Pathol)

The uneventful outcome in some of our cases indicates that a subset of EPS might follow a more indolent clinical course than previously appreciated. Additional studies are needed to validate whether any morphological and/or molecular attributes have a prognostic impact.

4 years ago

Clinical • Journal

TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • EWSR1 (EWS RNA Binding Protein 1) • GFAP (Glial Fibrillary Acidic Protein)

TP53 mutation • CDKN2A deletion • PAK4 deletion